Pod Insights Pharmacy Podcast Network Navigating Treatment of Dermatologic Inflammatory Conditions with Specialty Drug Therapies, with Vanderbilt Specialty Pharmacy, Vanderbilt Health | NASP Specialty Pharmacy Podcast About this episode In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Matthew G. Bowles, PharmD, MBA, CSP, Pharmacy Clinical Team Lead with Vanderbilt Specialty Pharmacy, Vanderbilt Health, and lead author on the study “Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey,” published February 2025 in the Journal of Managed Care & Specialty Pharmacy. They discuss the reasons for conducting and results of the study, as well as the impacts the study may have on specialty and managed care pharmacy.
Transcript 0:07 Speaker 00 Thanks for listening to the Pharmacy Podcast Network.
0:24 Speaker 01 You're listening to the NASP Specialty Pharmacy Podcast, a collaboration between the National Association of Specialty Pharmacy and the Pharmacy Podcast Network. Each episode dives deep into trends, challenges, innovations, and patient-centric practices shaping the future of this dynamic and rapidly evolving industry. Whether you're a pharmacist or healthcare provider, patient advocate or industry leader, you'll hear expert insights, real-world evidence, and thought-provoking discussion that highlights all that makes specialty pharmacy special.
0:57 Speaker 02 In support of NASP's mission to empower specialty pharmacy stakeholders to advance the standard of patient care, NASP supports a free-market healthcare system in which all specialty pharmacies compete on the same fair and level playing field, because that is in the best interest of the patients we collectively serve. NASP is committed to working with all stakeholders and policymakers to ensure that all patients have access to the life-saving medications they need and the high-touch patient care and support services they deserve from the pharmacy of their choosing.
1:28 Speaker 03 Hello, my name is Sheila Arquette, and I am the President and CEO of the National Association of Specialty Pharmacy. I am delighted to welcome my very special guest, Matthew G. Bowles, to this episode of the NASP Podcast. Matthew Bowles, PharmD, MBA, CSP, is a pharmacy clinical team lead with Vanderbilt Specialty Pharmacy Vanderbilt Health. He is the primary clinical pharmacist in dermatology and the clinical lead over dermatology, asthma, allergy, and endocrinology clinics. Dr. Bowles holds a PharmD and MBA from the University of Kentucky. Matt, thanks so much for joining me today.
2:05 Speaker 04 Thank you for having me, Sheila.
2:07 Speaker 03 So tell us a little bit about your role within Vanderbilt Specialty Pharmacy and your practice site.
2:13 Speaker 04 I have actually been at VSP now for over 10 years, which is crazy. It's flown by. I started out as a floater pharmacist and then soon moved into the dermatology role. I'm also a clinical team lead, as you had mentioned. And then as the dermatology pharmacist, I work directly with the providers. I'm on all specialty medications that they prescribe. And as clinical team lead, I am the immediate supervisor of the dermatology, asthma and allergy and endocrinology clinical pharmacist. Regarding the practice site, the Vanderbilt Dermatology Clinic is a very large practice.
2:55 Speaker 04 We have over 20 attendings, three mid-level providers and 15 residents. We also have two main sites and two satellite sites that some of the providers go to one day a week.
3:11 Speaker 03 Because your practice is centered just in Nashville with that many providers, like how far is your reach?
3:18 Speaker 04 So we have one major site in Nashville, another site down in Franklin, which is not too far from Nashville. And then we have a satellite site that's also in Nashville, just in a different area of the city, as well as another site that's about an hour from Nashville.
3:42 Speaker 04 Within dermatology, we have two specialty pharmacists. That is a recent change just because of the growth. So there are, there's myself and another pharmacist. And we do have two technicians that are also with us in dermatology that are integrated into the outpatient dermatology clinic.
4:00 Speaker 03 Oh my gosh, that's awesome. I just think back when I was in pharmacy school, right? That was all like, hopefully maybe someday that those types of things, those opportunities would be available. So that's awesome.
4:10 Speaker 04 Yeah, it's been very interesting since I was, I've been here since day one with dermatology and how much it has grown.
4:19 Speaker 03 Awesome. So let's talk a little bit about your project titled Getting to Specialty Treatment in Dermatologic Inflammatory Conditions: Treatment Requirements in the Patient Journey. This was recently published in the Journal of Managed Care in Specialty Pharmacy. So what made you decide to conduct this study?
4:37 Speaker 04 As dermatology, you know, I saw a major uptick in special medications being approved by the FDA for atopic dermatitis, enzuriasis, and other dermatological indications over the past several years. We started seeing a large number of patient referrals that were coming to us where the patient did not start due to step therapy requirements. And oftentimes, we would see the patient coming back soon after or being referred back to us after they had failed the step therapy. And I'll kind of add there, I'm kind of like our process. So the provider decides to start
5:19 Speaker 04 a patient with a special medication, and then they send the referral to us, just a message saying, hey, I want to get this patient started on this medication for this diagnosis. And then our technician does the benefits investigation and the prior authorization with the insurance. And then the pharmacist, if needed, does the appeal if it was denied. And then we also help with the financial assistance portion of it, if it's a copay card, or if they're needing, you know, something internally that Vanderbilt offers, or programs outside with a patient assistance program through the manufacturer, other type of financial
5:59 Speaker 04 assistance that's available. And then we also counsel the patient. And then also, every single patient, regardless of the pharmacy they use, we are the direct contact regarding their special medication. So if they have been on it for six months and they're using another, you know, using a pharmacy and having issues, they have our direct number to reach out so that we can help, you know, troubleshoot what the issue is.
6:27 Speaker 03 Oh, that's amazing. You're like an extension, right, of that provider's office, providing that, that clinical drug.
6:34 Speaker 04 Yeah, we, we are pretty much fully embedded with, you know, with the providers. So a lot of times I feel like I'm more on the provider's side of things than the pharmacy side of things, just because we are so involved in, you know, the special medication process.
6:51 Speaker 03 That's awesome.
6:52 Speaker 04 And, you know, looking at, going back to the project, that is kind of why we were able to see, you know, kind of this breakdown that was occurring with, you know, the referral process of, you know, the patient being referred and then not getting started on medication. So when we started looking at this project, the objective was to evaluate medication outcomes and the time requirements to access therapy and patients required to use a step therapy or a formulary alternative after being prescribed a special medication. We did just look at psoriasis and atopic dermatitis with our patients.
7:31 Speaker 03 So what did your study find?
7:34 Speaker 04 Um, well, so the first thing when we started looking at things, we wanted to look at formulary alternatives and step therapies. Formulary alternatives, they are other special medications. They're preferred by the insurance. These are typically in the same class, but we did find that this approval time was much less than step therapy. So in the study, and we mostly looked at step therapies, which are typically medications that are required prior to getting approved for special medication. They are typically much cheaper, but oftentimes have more side effects and require much more monitoring for the provider and the patient.
8:17 Speaker 04 So we conducted a single center retrospective review of data collected from our electronic health record as well as our specialty pharmacy management system. We included any patients that were referred by the dermatology provider for psoriasis or atopic dermatitis that was discontinued because the PBM or payer was requiring the patient to try a step therapy or formulary alternative between January 2021 and June 2022.
8:49 Speaker 04 The, we did look at the primary outcome, which is the number of days for the referral for the special medication and then when they came back after failing the step therapy. And then the secondary income was the number of patients that failed step therapy or formulary alternative and were referred back to the specialty pharmacy as well as the number of patients that did not start special medication and the reasoning behind that. So, you know, our study, every patient, what we did think was very interesting, every single patient had already trialed and failed topical corticosteroids. So they had already done a step therapy when we were, you know, submitting for approval for the special medication.
9:33 Speaker 04 But most insurances require at least one more step therapy outside of the topical corticosteroid. Most of the times it would be a topical calcineurin inhibitor or methotrexate.
9:44 Speaker 03 Oh, wow.
9:45 Speaker 04 And, and so that our findings, which was a huge, you know, 60% or 37 patients failed the step therapy with a medium timeframe of just 75 days. And we had 25 patients that were included in the study that were not started on special medication, but only five of those patients benefited from the step therapy and continued the step therapy. We did have 15 patients that were lost the follow-up. It is very difficult to get into our site just because of the, it's a very busy clinic and just,
10:30 Speaker 04 you know, we have so many providers, but we probably could have at least another 10 for the demand. So we do have patients lost the follow-up for that reason. And then we did have two patients that had psoriatic arthritis and typically that's handled by rheumatology. So they were able to bypass step therapy requirement by going to rheumatology and they were started on the specialty medication.
10:54 Speaker 03 Okay. So what are the potential impacts of your study on specialty and managed care pharmacy?
11:03 Speaker 04 With specialty pharmacy, you know, I think conducting, you know, a thorough medical history of the patients and what they have tried in the past, a lot of times when patients come to our practice, they've already seen a local provider, you know, even a PCP that has already prescribed them topicals, or they may have seen a local dermatologist, but then they, you know, were then sent to Vanderbilt and referred to one of our providers. So I think the specialty pharmacy and the dermatology providers, just having a thorough medical history is one thing that I think is very important.
11:45 Speaker 04 You know, with managed care, I think the managed care stakeholders should consider the impact of, you know, cost containment strategies on patients' ability to start the needed treatment. Also with dermatology providers, you know, having them understand that most insurances do require specific step therapies, and just having those step therapies done on the front end would help decrease that timeframe to get the specialty medication eventually approved. But on the flip side of that, you know, providers can have, you know, they can really push with the findings we found with 60% of the patients coming back and failing the step
12:30 Speaker 04 therapy. It just goes to show that it's just a delay tactic. And, you know, providers do, you know, these patients have moderate to severe psoriasis atopic dermatitis and typically are going to end up on a specialty medication.
12:46 Speaker 03 Right. Are they able to share that data back with like the payers or the PBMs to say, hey, look at, right? 60% of the people still have to go on, or is that not effective in having them look at their policies?
13:02 Speaker 04 I think they could definitely share the data and the findings, but a lot of times, you know, the PPMs and payers, they are just kind of, they have their guidelines and their requirements and it's really hard to get them to change that at all, even with, you know, when appealing, you know, they're saying, you know, these are our findings and the patient's going to require this because they're so, they have moderate to severe. It's still a lot of times, I don't know with the findings, if they would be able to get the payers to really go the other direction.
13:43 Speaker 03 Right. Okay. Just wondering. So what are the next steps with the results of your project?
13:51 Speaker 04 One is sharing the findings with my dermatology providers that I work with on a daily basis. And then the other is, you know, at the NASP conference, when I presented my findings and poster, I had several people actually ask, did the patients actually benefit from the specialty medication that they started and were they still taking it? So at the PQA annual meeting, which is next month in Tampa, I will be presenting where patients were 12 months after starting the specialty medication.
14:28 Speaker 03 Awesome. And those are all your patients, right? So that there's no any kind of control with like maybe practitioners who aren't embedded with the, with the clinical practice?
14:37 Speaker 04 That is correct. They're all our patients.
14:39 Speaker 03 Okay. All right. Cause I'm sure that is, you know, has a, has a tremendous positive impact on, at least I would, I would think adherence or if the patient isn't responding, right? Then switching them to a product that perhaps they would respond to.
14:54 Speaker 04 Exactly.
14:56 Speaker 03 Awesome. Well, any, any final thoughts, Matt? Any closing thoughts?
14:59 Speaker 04 Really, the, you know, after doing this study, the findings were very interesting, I thought, just because it goes to show you, insurances and providers definitely have two totally different ideas on, you know, what patients should be on. And a lot of times, you know, the insurance is dictating what the provider is having to prescribe initially. And the findings specifically, you know, show that typically, the patients do end up on what the provider initially wanted them to start.
15:37 Speaker 03 Right. That's quite, that's quite telling, right? So was that, you know, those whatever months, weeks, whatever it was that the patient was on, that prerequisite drug, you know, is that just a waste, right? Both in terms of, you know, the patient's time and, you know, time that they're not controlled, their disease isn't controlled, but then also the money spent on that prerequisite drug?
15:58 Speaker 04 Yeah, you know, a lot of times, they have another, you know, office visit to, to see how they're doing on their step therapy. And, you know, if they are doing something like methotrexate, they're having to pay for the labs and things like that. So it definitely, there are costs associated with that as well.
16:18 Speaker 03 Right. So this seems like a definite, I think it's a great, great project. The data is excellent, right, to kind of facilitate that conversation of geez, how do we work better together, right, keeping the patient at the center of this? Well, thanks so much, Matt, for chatting with me and sharing this valuable information.
16:36 Speaker 04 Really appreciate you having me today.
16:38 Speaker 03 And I look forward to seeing, to seeing you at PQA. And as a reminder, NASP corporate members are invited to be my guests on one complimentary podcast per year. For more information about this or other NASP membership benefits and events, please feel free to reach out to [email protected] or visit our website, www.naspnet.org. Until next time, have a great day.
Previous Revealing the Power of Pharmacy Data: Automation Insights with Dr. Matthew Song | Pharmacy Tech Trends: PrimeRx Next The Mythbusting Episode | Essential: Pharmacy Compounding Podcast APC Page updated November 14, 2026 · transcript and summary are machine-generated